The dollar value of insider sales is negligible relative to market cap, indicating routine portfolio diversification rather than a negative signal. Monitor next earnings release for any operational updates that could affect the stock's volatility.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $11.83entry
- T+1 · 16h ago −4.48%α −2.57% · $11.30
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two NovoCure insiders, including the CFO and CHRO, sold shares in open-market transactions totaling $103K over a one-week period. The sales are small relative to the company's $1.4B market cap (0.007%), making them routine and not indicative of material non-public information.
Key Financial Metrics
Key Facts
- CFO Brackmann Christoph sold 7,343 shares at $12.86 for $94K on Nov 9, 2026
- CHRO Puri Michal Nath sold 660 shares at $13.24 for $9K on Nov 2, 2026
- Total open-market sales by insiders: $103K, or 0.007% of market cap
- Neither sale was executed under a 10b5-1 plan
- No insider purchases were reported in the cluster window
Financial Impact
Total insider sales of $103K, immaterial relative to $1.4B market cap
Risk Factors
- Insider sales, while small, could be perceived negatively by retail investors if highlighted out of context
- No insider buying to offset the selling pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NVCR-1794517751336 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Viewing Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers